A number of analysts have recently weighed in on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares. Analysts at Piper Jaffray initiated coverage on shares of Vanda Pharmaceuticals in a research note on Tuesday, November 26th. They set an “overweight” rating and a $21.00 price target on the stock. On a related note, analysts at Jefferies Group raised their price target on shares of Vanda Pharmaceuticals from $13.00 to $20.00 in a research note on Friday, November 15th. They now have a “buy” rating on the stock. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) stock opened at $16.50 in last session, and closed at $17.53, while the day range of VNDA stock is $16.43-$18.00. The stock showed a positive weekly performance of 17.02%.
Oncothyreon (NASDAQ:ONTY) issued its quarterly earnings data on Thursday. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.10) by $0.01, ARN reports.Oncothyreon Inc (USA) (NASDAQ:ONTY) stock opened at $3.90, in last session and closed at $3.89, by gained 4.57%. The 52 week range was $1.55-$4.08.Company’s market capitalization is $269.63 million.
Albany Molecular Research (Nasdaq:AMRI) has been upgraded by TheStreet Ratings from hold to buy. The company’s strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins.Albany Molecular Research, Inc. (NASDAQ:AMRI) stock gained 5.85% and finished the last session at $17.18.The EPS of the stock remained 0.40.Company’s market capitalization is $542.85 million.
TG Therapeutics, Inc. (NASDAQ:TGTX) is betting on a couple of formulations to fight certain types of leukemia and lymphoma. Both the compounds — TG-1101 and TGR-1202 — are under development and undergoing clinical trials. TG Therapeutics is focused on developing cutting edge drugs such as monoclonal antibodies and delta inhibitors to fight lymphomas, leukemia, and other forms of cancer and hematological disorders. TG Therapeutics, Inc. (NASDAQ:TGTX) stock opened the session at $7.39, and closed the session at $7.55. The 52 week range of the TGTX stock remained $2.97-$8.02 and the day range was $7.37-$8.02.